PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
BörsenkürzelPAVMZ
Name des UnternehmensPAVmed Inc
IPO-datumJul 27, 2016
CEODr. Lishan Aklog, M.D.
Anzahl der mitarbeiter39
WertpapierartCompany Warrant
GeschäftsjahresendeJul 27
Addresse360 Madison Avenue
StadtNEW YORK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl10017
Telefon12129494319
Websitehttps://pavmed.com/
BörsenkürzelPAVMZ
IPO-datumJul 27, 2016
CEODr. Lishan Aklog, M.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten